Vectron Biosolutions to Boost Protein Production Offering with Acquisition of Secretion Platform from T3S Technologies and $2.7M Series A Financing Round

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): PR Newswire
  • Source:
    PR Newswire US. 06/17/2021.
  • Additional Information
    • Alternate Title:
      VECTRON-Acquisition
    • Subject Terms:
      Norway
    • Abstract:
      TRONDHEIM, Norway, June 17, 2021 /PRNewswire/ -- Vectron Biosolutions, upstream experts providing expression tools and services in biomanufacturing, announced today it has raised $2.7 million in a Series A financing round led by Dynamk Capital as well as the acquisition of a bacterial secretion platform from Utah based T3S Technologies. The acquisition of T3S Technologies' secretion platform combined with Vectron's core expression technology and additional financing will significantly boost Vectron's position as a leading partner to biomanufacturers looking to reduce costs associated with the production of recombinant proteins or for solutions to advance their challenging proteins to the market. [ABSTRACT FROM PUBLISHER]